CAMP4 Therapeutics

OverviewSuggest Edit

CAMP4 Therapeutics is a biotechnology company. It offers Gene Circuitry Platform, an approach capable of mapping the transcriptional machinery and network of signaling pathways that control gene expression across cells in the human body.

TypePrivate
Founded2016
HQCambridge, MA, US
Websitecamp4tx.com

Latest Updates

Employees (est.) (Jun 2022)61(+2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at CAMP4 Therapeutics

Josh Mandel-Brehm

Josh Mandel-Brehm

President & Chief Executive Officer, Director
Jorge Conde

Jorge Conde

Director
David Bumcrot

David Bumcrot

Chief Scientific Officer
Michael Higgins

Michael Higgins

Diretor
Kelly Gold

Kelly Gold

Chief Business Officer, SVP Finance
Amir Nashat

Amir Nashat

Director
Show more

CAMP4 Therapeutics Office Locations

CAMP4 Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
One Kendall Square, Binney St
Show all (1)

CAMP4 Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

CAMP4 Therapeutics total Funding

$30 m

CAMP4 Therapeutics latest funding size

$30 m

Time since last funding

4 years ago

CAMP4 Therapeutics investors

CAMP4 Therapeutics's latest funding round in May 2018 was reported to be $30 m. In total, CAMP4 Therapeutics has raised $30 m
Show all financial metrics

CAMP4 Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

CAMP4 Therapeutics Online and Social Media Presence

Embed Graph

CAMP4 Therapeutics News and Updates

OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics

MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT te…

CAMP4 Therapeutics Blogs

CAMP4 Therapeutics Promotes Kelly Gold to Chief Financial Officer

Finance and business development veteran and founding member of CAMP4 leadership team CAMBRIDGE, Mass., April 19, 2022 – CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNAs to upregulate genes and restore healthy expression, today announced that it has appointed Kelly…

CAMP4 Therapeutics Appoints Veteran Drug Developer Ann Barbier, M.D., Ph.D. as Chief Medical Officer

Al Sandrock, M.D., Ph.D. joins Scientific Advisory Board CAMBRIDGE, Mass., March 14, 2022 – CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNAs to upregulate genes and restore healthy expression, today announced that it has appointed Ann Barbier, M.D., Ph.D., as Chief…

CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting

Upregulation of SCN1A gene expression by targeting regulatory RNAs Company to advance oligonucleotide development candidate for Dravet Syndrome; expected to file IND by YE 2022 CAMBRIDGE, Mass., December 3, 2021 – CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore hea…

CAMP4 Presents First Preclinical Data Demonstrating the Therapeutic Potential of its RNA Actuating Platform at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Novel approach to upregulating gene expression by targeting regulatory RNAs Company to advance development candidate for urea cycle disorders; expected to enter clinical trials in 2023 CAMBRIDGE, Mass., September 27, 2021 – CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to r…

CAMP4 Therapeutics Expands Leadership and Board of Directors

Kelly Gold promoted to Chief Business Officer and SVP, Finance Michelle Gates appointed SVP, Chief People Officer Ravi Thadhani, M.D., M.P.H. named to board of directors   CAMBRIDGE, Mass., July 13, 2021 – CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy gen…

CAMP4 Raises $45 Million to Usher in a New Era of Programmable Therapeutics to Upregulate Genes

Proceeds to fuel expansion of RNA Actuating Platform™ designed to harness the power of regulatory RNA to restore healthy gene expression Company advancing preclinical pipeline initially focused on CNS and liver diseases; first IND expected in 2022 Funding led by 5AM Ventures and Northpond Ventures, …

CAMP4 Therapeutics Frequently Asked Questions

  • When was CAMP4 Therapeutics founded?

    CAMP4 Therapeutics was founded in 2016.

  • Who are CAMP4 Therapeutics key executives?

    CAMP4 Therapeutics's key executives are Josh Mandel-Brehm, Jorge Conde and David Bumcrot.

  • How many employees does CAMP4 Therapeutics have?

    CAMP4 Therapeutics has 61 employees.

  • Who are CAMP4 Therapeutics competitors?

    Competitors of CAMP4 Therapeutics include Oxford BioTherapeutics, MicrofluidX and Affinia Therapeutics.

  • Where is CAMP4 Therapeutics headquarters?

    CAMP4 Therapeutics headquarters is located at One Kendall Square, Binney St, Cambridge.

  • Where are CAMP4 Therapeutics offices?

    CAMP4 Therapeutics has an office in Cambridge.

  • How many offices does CAMP4 Therapeutics have?

    CAMP4 Therapeutics has 1 office.